Mpox Vaccine Emergency Stockpile Receives Boost
The addition of 225,000 vaccine doses ensures more equitable, timely access for populations facing mpox outbreaks.
Updated on Oct. 27, 2026 in COVID-19
Live Poll
Do you trust pharmaceutical partnerships to adequately secure and distribute vaccines for future global health emergencies?
Bavarian Nordic has donated 75,000 doses of its MVA-BN vaccine to a new global emergency stockpile for mpox. The company has also secured a contract to supply an additional 150,000 doses to the reserve, which is managed by the International Coordinating Group on Vaccine Provision.
Why it matters
The creation of this global emergency stockpile aims to provide timely, equitable access to vaccines for countries facing mpox outbreaks. By centralizing supply, health organizations can respond more rapidly to containment needs than through individual procurement.
Bavarian Nordic confirmed the commitment of 75,000 donated doses and a 150,000-dose supply contract for the global emergency stockpile. While MVA-BN is currently prequalified by the WHO for individuals aged 12 and older, the logistical scale-up for global distribution remains in progress.
The players
Bavarian Nordic
A biotechnology company headquartered in Denmark that develops and manufactures vaccines for infectious diseases including mpox.
International Coordinating Group on Vaccine Provision
An international body that manages the allocation and deployment of emergency vaccine supplies during outbreaks.
Gavi, the Vaccine Alliance
A global health partnership that provided the initial funding to establish the emergency vaccine stockpile.
The details
The MVA-BN vaccine is a non-replicating mpox immunization that triggers an immune response without the risk of causing the disease. It is currently approved in multiple jurisdictions, including the European Union, the United States, and the United Kingdom, and the European Commission has expanded authorization to include children aged 2 to 12. The International Coordinating Group manages the deployment of these doses to ensure they reach regions during active outbreak scenarios.
Timeline
2022-2024: Bavarian Nordic supported vaccine access in 70 countries.
2024: MVA-BN vaccine received World Health Organization prequalification.
October 27, 2026: Bavarian Nordic announced the donation and contract.
Health Landscape
The establishment of this stockpile reflects a strategic shift toward centralized, global readiness for mpox. It builds upon the existing framework overseen by the International Coordinating Group to ensure rapid deployment during future outbreaks.
This development ensures that vaccines are more readily available for public health response in affected regions worldwide. If you are in an area currently experiencing an outbreak, consult your local health authority regarding vaccination eligibility and availability.
The takeaway
Equitable access to vaccination is a cornerstone of managing mpox outbreaks and protecting vulnerable populations. Always verify your local eligibility and vaccination guidelines by speaking with a healthcare provider or checking your regional public health agency website.
Further reading
Learn more about global disease prevention strategies in our COVID-19 section.
More information
For more information on vaccine development and production, visit the Bavarian Nordic company information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical partnerships to adequately secure and distribute vaccines for future global health emergencies?
